Electronic informed consent, or eConsent, is one technological advancement introduced to clinical trials that is escalating in its adoption. In this blog, get 5 tips for implementing and preparing for eConsent.
A unified EDC platform that includes a built-in payment manager ensures efficient, accurate administration of all processes in one central system, rather than jumping from platform to platform.
The TransPerfect Life Sciences Trial Interactive team was excited to attend the 2017 TMF Summit in London this October, where discussions on the movement from paper to eTMF continued to be a focus.
How the right technology can dramatically improve compliance, efficiency, and visibility in trials involving imaging.
What clinical researchers should consider as they start to make the essential pivot toward electronic data capture.
To enable the completion of clinical trials as safely, efficiently and quickly as possible, PerkinElmer Informatics’ clinical solutions streamline clinical trial data visualization and analysis with real-time access to clinical data in all phases of clinical development.
Learn how PerkinElmer’s clinical solutions give clinical operations organizations the unprecedented ability to reduce the time, cost and risk of running clinical trials while accelerating the time to market for products across the entire portfolio of clinical candidates.
Achieve clinical trial operations excellence using this an innovative solution that gives clinical operations organizations the unprecedented ability to reduce the time, cost, and risk of running clinical trials while accelerating time to market for products across the entire portfolio of clinical candidates.
Gilead Sciences’ previous studies of Ranexa (ranolazine) relied on data from exercise treadmill parameters as the primary endpoint. But collecting data in this manner is costly, logistically challenging, and bears questionable clinical relevance — especially at the individual patient level. Learn how Gilead Sciences successfully utilized ERT handhelds to collect regulatory-compliant, patient-driven data in support of the primary efficacy endpoint in a Phase IV study of Ranexa.
The objective of this study was to compare the equivalence of a new version of the electronic Columbia-Suicide Severity Rating Scale that was administered on a tablet device. The results supported the validity and reliability of the new tablet-based electronic Columbia-Suicide Severity Rating Scale and allow its inclusion in a wider range of clinical studies, particularly where a tablet is also being used to collect other study data.